skip to main content

Obesity pharmacotherapy — SCE Endocrinology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateObesity/LipidObesity pharmacotherapySCE Endocrinology

A 50-year-old woman has obesity, hypertension and type 2 diabetes. She wants anti-obesity medication and has eGFR 55 ml/min/1.73 m2. There is no pancreatitis history or medullary thyroid cancer. What is the most appropriate management principle?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: AUse medication as part of a structured obesity pathway with monitoring

Anti-obesity pharmacotherapy should sit within a structured pathway including nutrition, activity, behavioural support, monitoring and stopping rules. Medication without follow-up misses adverse effects and non-response. Thyroid hormone and diuretics are unsafe weight-loss strategies in euthyroid patients.

Reference: NICE NG246; BNF